Kinnate Biopharma Stock Doubles As IPO Begins Trading

Kinnate Biopharma Stock Doubles As IPO Begins Trading

Kinnate Biopharma is a preclinical biotech focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat cancers. The IPO raised $240 million.